Skip to main content
. 2015 Sep 21;34(6):581–587. doi: 10.1200/JCO.2015.61.8413

Fig 3.

Fig 3.

(A) Cumulative incidence of cardiac events by treatment arm. (B) Cumulative incidence of cardiac events for nontrastuzumab arm (arm A) versus trastuzumab arms (arms B and C). AC, doxorubicin plus cyclophosphamide; T, paclitaxel; H, trastuzumab.